سعر بيلاستوميد 12.5مجم/5مل شراب 120 مل 2024

Bilastine oral syrup 12.5 mg/5 mL (2.5 mg/mL) 120 mL — Egyptian Biomed product.

• Symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria in adults and adolescents 12 years and over.UK eMC / MHRA

• Common: headache, somnolence. Uncommon include dizziness, fatigue, abdominal discomfort, dry mouth. Post-marketing: palpitations, tachycardia, hypersensitivity (including anaphylaxis, angioedema), vomiting.General active-ingredient information · UK eMC / MHRA

• Hypersensitivity to bilastine or to any of the excipients.General active-ingredient information · UK eMC / MHRA

• In moderate or severe renal impairment, avoid coadministration with P-glycoprotein inhibitors (e.g. ketoconazole, erythromycin, ciclosporin, ritonavir, diltiazem). Caution if risk of QT prolongation. Do not use in children under 2 years or body weight <15 kg.General active-ingredient information · UK eMC / MHRA

• Food / fruit juice (incl. grapefruit)ModerateFood and grapefruit juice reduce bilastine oral bioavailability by about 30%; take on an empty stomach timing as labelled.UK eMC / MHRA
• P-gp inhibitors (ketoconazole, erythromycin, diltiazem, ciclosporin)ModerateIncrease bilastine exposure (AUC/Cmax); generally without change in safety profile in studies, but avoid with P-gp inhibitors in moderate/severe renal impairment.UK eMC / MHRA

• Limited data in pregnant women. Animal studies do not indicate direct/indirect reproductive toxicity. Preferable to avoid use during pregnancy as a precaution.General active-ingredient information · UK eMC / MHRA
• Excretion in human milk not studied; animal data show excretion in milk. Decide whether to continue breastfeeding or therapy considering benefit to child and mother.General active-ingredient information · UK eMC / MHRA

• Bilastine: Non-sedating long-acting selective peripheral H1-receptor antagonist without muscarinic affinity (UK Ilaxten SmPC).